Therapeutic effect of sintilimab on esophageal cancer patients with varying levels of carcinoembryonic antigen
Objective To analyze the therapeutic effect of sintilimab on esophageal cancer patients with varying levels of carcinoembryonic antigen(CEA).Methods A total of 86 esophageal cancer patients admitted from January 2020 to January 2024 were selected as the study subjects.With the threshold of CEA at 3.65ng/mL,43 patients with CEA＞3.65ng/mL were selected as the control group,and 43 patients with CEA≤3.65ng/mL were selected as the study group.Both groups of patients were treated with sintilimab.Clinical efficacy,cellular immune function,tumor markers,stress hormones,and prognostic indicators were compared between two groups.Results Compared with those of the control group,patients in the study group had a better clinical efficacy(P＜0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+,cardiac troponin Ⅰ(cTnI),B-type natriuretic peptide(BNP),the Karnofsky Performance Scale(KPS)score,and 36-Item Short-Form Survey(SF-36)score significantly increased in both groups,and they were significantly higher in the study group(P＜0.05).After treatment,the levels of hemoglobin,albumin,prealbumin,L3 skeletal muscle mass index,cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125),growth hormone(GH),prolactin(PRL),basic fibroblast growth factor(bFGF),and insulin-like growth factor 1(IGF-1)significantly decreased in both groups,and they were significantly lower in the study group(P＜0.05).Conclusion Esophageal cancer patients treated with sintilimab have a good efficacy.Compared to those with high CEA expression,sintilimab has a better therapeutic effect on esophageal cancer patients with low CEA expression.It can reduce tumor marker levels,improve the immune function,prognosis,and recovery.
NETL
NSTL
万方数据
